232
Participants
Start Date
June 30, 2003
Study Completion Date
March 31, 2004
Atorvastatin
In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
Atorvastatin
In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
Pfizer Investigational Site, Brussels
Pfizer Investigational Site, Antwerp
Pfizer Investigational Site, Merksem
Pfizer Investigational Site, Wilrijk
Pfizer Investigational Site, Mortsel
Pfizer Investigational Site, Edegem
Pfizer Investigational Site, Mechelen
Pfizer Investigational Site, Brasschaat
Pfizer Investigational Site, Liège
Pfizer Investigational Site, Seraing
Pfizer Investigational Site, Gilly (charleroi)
Pfizer Investigational Site, La Louvière
Pfizer Investigational Site, Wingene
Pfizer Investigational Site, Roeselare
Pfizer Investigational Site, Menen
Pfizer Investigational Site, Ghent
Pfizer Investigational Site, Genk
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY